Clinical Trial Update: Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis [Phase 2, Phase 3]

View source ↗

Summary

A phase II/III seamless clinical trial evaluating MG-K10, a humanized monoclonal antibody, for seasonal allergic rhinitis, currently in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• MG-K10

Snippet

Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Conditions: Seasonal Allergic Rhinitis | Phase 2, Phase 3 | Status: RECRUITING